The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 March 2026•

1 min read

Spectral Medical Announces Publication of Tigris Trial Results in The Lancet

Collage of scientific publication "THE LANCET" with clinical research graphs, lab equipment, and a medical room illustration.

Key Facts

1Spectral Medical and Vantive announced the publication of complete Tigris trial results in The Lancet Respiratory Medicine.

2 months ago

Version History

1 additional source confirmed this story

Version 12 months ago

Spectral Medical Inc. (TSX: EDT) and its partner Vantive have announced the publication of the full results from the Tigris clinical trial in the prestigious journal The Lancet Respiratory Medicine. The randomized-controlled trial evaluated the efficacy and safety of Polymyxin B Hemoadsorption (PMX) therapy in adult patients suffering from endotoxic septic shock. The published data provides a comprehensive view of patient outcomes, highlighting significant survival benefits and safety profiles over the study period. This peer-reviewed validation is a critical milestone for Spectral Medical, as it reinforces the clinical evidence supporting its innovative PMX treatment. Investors view the publication in a top-tier medical journal as a positive signal for the company's future regulatory and commercial prospects. The Tigris trial results are expected to bolster the medical community's confidence in adopting this therapy for critical care applications.